+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pulmonary Fibrosis Drug"

From
From
From
From
From
From
Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032

  • Report
  • August 2022
  • 109 Pages
  • Global
From
From
From
From
From
Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026 - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026

  • Report
  • March 2019
  • 47 Pages
  • Global
From
Loading Indicator

The Pulmonary Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pulmonary fibrosis, a chronic and progressive lung disease. These drugs are used to reduce symptoms, slow the progression of the disease, and improve quality of life. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. In some cases, lung transplantation may be recommended. The Pulmonary Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of these companies include Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Novartis, and Vertex Pharmaceuticals. Show Less Read more